Phase 2Active, not recruitingNCT04589325

I-DIT: ixekizumab anti-IL-17 in new-onset T1D

What this study tests

Swedish randomized phase 2 trial testing ixekizumab, an anti-IL-17A antibody used in psoriasis, for preservation of residual insulin secretion in adults with new-onset T1D.

Editorial review: 2026-08-27.

Registry checked: 2026-09-17. Registry’s own update: 2026-04-27.

Source dates appear in the references where available; this record has no dated citation metadata.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?: Adults 18-45 with new-onset T1D. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results: No results posted yet.Read the result sources and their limitations →
Important harms: Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval: Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?: Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

Residual insulin secretion

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

[1]
NCT04589325: I-DIT: ixekizumab anti-IL-17 in new-onset T1D · Trial registry